Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Nonclinical pharmacology and toxicology of the first biosimilar insulin glargine drug product (BASAGLAR®/ABASAGLAR®) approved in the European Union.
Byrd RA, Owens RA, Blackbourne JL, Coutant DE, Farmen MW, Michael MD, Moyers JS, Schultze AE, Sievert MK, Tripathi NK, Vahle JL. Byrd RA, et al. Among authors: michael md. Regul Toxicol Pharmacol. 2017 Aug;88:56-65. doi: 10.1016/j.yrtph.2017.05.013. Epub 2017 May 17. Regul Toxicol Pharmacol. 2017. PMID: 28526658
Glucagon as a target for the treatment of Type 2 diabetes.
Sloop KW, Michael MD, Moyers JS. Sloop KW, et al. Among authors: michael md. Expert Opin Ther Targets. 2005 Jun;9(3):593-600. doi: 10.1517/14728222.9.3.593. Expert Opin Ther Targets. 2005. PMID: 15948676 Review.
Internalization and localization of basal insulin peglispro in cells.
Moyers JS, Volk CB, Cao JXC, Zhang C, Ding L, Kiselyov VV, Michael MD. Moyers JS, et al. Among authors: michael md. Mol Cell Endocrinol. 2017 Oct 15;454:23-38. doi: 10.1016/j.mce.2017.05.032. Epub 2017 May 30. Mol Cell Endocrinol. 2017. PMID: 28576743
Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors.
Sloop KW, Cao JX, Siesky AM, Zhang HY, Bodenmiller DM, Cox AL, Jacobs SJ, Moyers JS, Owens RA, Showalter AD, Brenner MB, Raap A, Gromada J, Berridge BR, Monteith DK, Porksen N, McKay RA, Monia BP, Bhanot S, Watts LM, Michael MD. Sloop KW, et al. Among authors: michael md. J Clin Invest. 2004 Jun;113(11):1571-81. doi: 10.1172/JCI20911. J Clin Invest. 2004. PMID: 15173883 Free PMC article.
Structure-Based Design of Active-Site-Directed, Highly Potent, Selective, and Orally Bioavailable Low-Molecular-Weight Protein Tyrosine Phosphatase Inhibitors.
He R, Wang J, Yu ZH, Moyers JS, Michael MD, Durham TB, Cramer JW, Qian Y, Lin A, Wu L, Noinaj N, Barrett DG, Zhang ZY. He R, et al. Among authors: michael md. J Med Chem. 2022 Oct 27;65(20):13892-13909. doi: 10.1021/acs.jmedchem.2c01143. Epub 2022 Oct 5. J Med Chem. 2022. PMID: 36197449 Free PMC article.
63 results